Human Microbiome Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Human Microbiome Market in 2025 is evaluated at USD 558.65 million. The global Market size was worth over USD 445.92 million in 2024 and is poised to grow at a CAGR of around 31.6%, reaching USD 15.83 billion revenue by 2037. North America is anticipated to collect USD 5.54 billion by 2037, fueled by rising pet adoption and an increase in government initiatives to study microbial communities.
The rising cases of lifestyle-related diseases such as diabetes and the increasing investment in biological drug development across the globe are expected to propel market growth. It is found that dysbiosis, or abnormalities in the microbiome, can lead to the development of several lifestyle disorders.
The rise in research activities about the impact of the microbiome on health and the development of microbiome-based goods and services is predicted to create the potential for market expansion over the estimated period. Additionally, increasing technological advancements are further believed to fuel the growth of the human microbiome market. For instance, it is now simpler and less expensive to investigate the microbiome owing to developments in DNA sequencing technology.
Human Microbiome Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Incidence of Respiratory Diseases – Ongoing studies state that the lung microbiome increases the proneness to respiratory diseases and influences responses to treatment. Hence, the surge in investment in comprehending the lung microbiome to develop both diagnostic and prognostic biomarkers for respiratory diseases in clinical settings will drive market growth.
- Increasing Prevalence of Gastrointestinal Disorders – According to a study, globally around 35% of people lived with functional gastrointestinal disorders in 2021. It is expected that with the growing cases of gastrointestinal disorders and digestive health, including diarrhea, constipation, and bowel incontinence, the rising influence of the human gut microbiome in both health and disease is slated to expand the market in the upcoming years.
- Rising Health Spending and Extensive Research About Human Microbiome – The increasing involvement of the human microbiome in human metabolism, nutrition, physiology, and immune function is responsible for several ongoing studies on the human microbiome and its function. The rising need to eliminate the growing healthcare expenditure worldwide by improving the gut microbiota and the human microbiome is poised to drive market expansion.
Challenges
- Strict Government Rules & Regulations- The emerging regulations by the government for the market are one of the major factors counted to slow down the market growth. For instance, probiotics are regarded as dietary supplements and no microbiome-based probiotics have received FDA approval as live biotherapeutic products (LBP).
- Lack of Knowledge about Human Microbiome Products
- Absence of Sufficient Research on the Human Microbiome
Human Microbiome Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
31.6% |
|
Base Year Market Size (2024) |
USD 445.92 million |
|
Forecast Year Market Size (2037) |
USD 15.83 billion |
|
Regional Scope |
|
Human Microbiome Segmentation
Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs)
The probiotics segment is set to gain the largest market share of 40% by the year 2037. The increasing prevalence of digestive diseases across the globe is driving the demand for probiotics as some probiotics can improve the immune system, reduce inflammation, and may even lower cholesterol. According to statistics, more than 35% of people around the world experience persistent digestive issues. It is assessed that live bacteria and yeasts called probiotics are beneficial to health, particularly the digestive system, and have been proven to be successful in treating common symptoms, including bloating, stomach pain, and diarrhea.
The drugs segment is counted to pool in the highest revenue, owing to the rising investment in the field of live biotherapeutics which is envisaged to develop pharmacologic treatments for a range of diseases.
Disease Type (Infectious Disease, Obesity, Diabetes, Gastrointestinal Diseases, Cancer, Cardiovascular Diseases)
The gastrointestinal diseases segment is speculated to garner a significant share of around 46% through 2037, as the development and treatment of gastrointestinal illnesses are significantly influenced by the human microbiome. Gut health could be improved and the risk of gastrointestinal disorders could be decreased with probiotics, prebiotics, and other microbiome-targeted medicines. This, as a result, is anticipated to create numerous opportunities for the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Disease Type |
|
|
Organism Type |
|
|
Application |
|
|
Technology |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Human Microbiome Industry - Regional Synopsis
North American Market Forecast
The human microbiome market in North America is poised to account for the largest share of 35% by the end of 2037, driven by rising pet adoption. The rising frequency of lifestyle illnesses in developed countries such as the United States is boosting the demand for microbiome-related goods and services, as people look for ways to enhance their gut health and overall health outcomes. According to data, the prevalence of age- and lifestyle-related diseases in the US is forecasted to rise by more than 15% over the next 20 years. Hence, the human microbiome market in North America will expand during the forecast period with an increase in government initiatives to enable the study of microbial communities to improve understanding of the microbiota and support human health in the region.
Europe Market Forecast
The Europe human microbiome market is estimated to be the second largest regional market with a share of about 25% by the end of 2037. The growth in research & development (R&D) activities for new applications of the human microbiome and the long-term vision of developing a life science ecosystem with the rising investments for biomedical research is predicted to expand the market in the region.
Companies Dominating the Human Microbiome Landscape
- Seres Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Evelo Biosciences, Inc.
- Synlogic, Inc.
- Second Genome Inc.
- Synthetic Biologics, Inc.
- YSOPIA Bioscience
- 4D Pharma plc
- DuPont de Nemours, Inc.
- BiomX Inc.
- Sun Genomics, Inc.
- Viome Life Sciences, Inc.
Recent Developments
- Viome Life Sciences, Inc. launched the CancerDetect test for oral and throat cancer. Further, this test also fills a market gap by offering advanced, early detection at the point when it is most controllable and is the first to find biomarkers for early-stage oral and throat cancers.
- Seres Therapeutics, Inc. teamed up with Bacthera to produce SER-109, for reoccurring Clostridium difficile infection (rCDI). Further, the collaboration enhanced the initial commercial manufacturing supply chain, which will strengthen SER-109's commercial production capacities and provide supply support.
- Report ID: 4062
- Published Date: May 08, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Human Microbiome Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
